NVO Quote, Financials, Valuation and Earnings

Biodexa Pharmaceuticals PLC has a net margin of 37.18% compared to Novo Nordisk AS's net margin of --. Novo Nordisk AS's return on equity of 84.88% beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.

Novo Nordisk AS has a consensus price target of $86.41, signalling upside risk potential of 28.89%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.94 which suggests that it could grow by 2041.28%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Novo Nordisk AS, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Novo Nordisk AS.

Novo Nordisk AS has a beta of 0.642, which suggesting that the stock is 35.798% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.167, suggesting its more volatile than the S&P 500 by 16.654%.

Novo Nordisk AS has a quarterly dividend of $1.14 per share corresponding to a yield of 2.48%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk AS pays 43.71% of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novo Nordisk AS quarterly revenues are $11B, which are larger than Biodexa Pharmaceuticals PLC quarterly revenues of --. Novo Nordisk AS's net income of $4.1B is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, Novo Nordisk AS's price-to-earnings ratio is 19.85x while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 6.85x versus 0.87x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.

DBV Technologies SA has a net margin of 37.18% compared to Novo Nordisk AS's net margin of --. Novo Nordisk AS's return on equity of 84.88% beat DBV Technologies SA's return on equity of --.

Novo Nordisk AS has a consensus price target of $86.41, signalling upside risk potential of 28.89%. On the other hand DBV Technologies SA has an analysts' consensus of $16.06 which suggests that it could grow by 64.81%. Given that DBV Technologies SA has higher upside potential than Novo Nordisk AS, analysts believe DBV Technologies SA is more attractive than Novo Nordisk AS.

Novo Nordisk AS has a beta of 0.642, which suggesting that the stock is 35.798% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.587, suggesting its less volatile than the S&P 500 by 158.693%.

Novo Nordisk AS has a quarterly dividend of $1.14 per share corresponding to a yield of 2.48%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk AS pays 43.71% of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novo Nordisk AS quarterly revenues are $11B, which are larger than DBV Technologies SA quarterly revenues of --. Novo Nordisk AS's net income of $4.1B is higher than DBV Technologies SA's net income of -$27.1M. Notably, Novo Nordisk AS's price-to-earnings ratio is 19.85x while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 6.85x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

Evaxion AS has a net margin of 37.18% compared to Novo Nordisk AS's net margin of -64.14%. Novo Nordisk AS's return on equity of 84.88% beat Evaxion AS's return on equity of --.

Novo Nordisk AS has a consensus price target of $86.41, signalling upside risk potential of 28.89%. On the other hand Evaxion AS has an analysts' consensus of $13.25 which suggests that it could grow by 404.76%. Given that Evaxion AS has higher upside potential than Novo Nordisk AS, analysts believe Evaxion AS is more attractive than Novo Nordisk AS.

Novo Nordisk AS has a beta of 0.642, which suggesting that the stock is 35.798% less volatile than S&P 500. In comparison Evaxion AS has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Novo Nordisk AS has a quarterly dividend of $1.14 per share corresponding to a yield of 2.48%. Evaxion AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk AS pays 43.71% of its earnings as a dividend. Evaxion AS pays out -- of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novo Nordisk AS quarterly revenues are $11B, which are larger than Evaxion AS quarterly revenues of $3M. Novo Nordisk AS's net income of $4.1B is higher than Evaxion AS's net income of -$1.6M. Notably, Novo Nordisk AS's price-to-earnings ratio is 19.85x while Evaxion AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 6.85x versus 1.74x for Evaxion AS. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics has a net margin of 37.18% compared to Novo Nordisk AS's net margin of --. Novo Nordisk AS's return on equity of 84.88% beat Viking Therapeutics's return on equity of --.

Novo Nordisk AS has a consensus price target of $86.41, signalling upside risk potential of 28.89%. On the other hand Viking Therapeutics has an analysts' consensus of $90.26 which suggests that it could grow by 185.37%. Given that Viking Therapeutics has higher upside potential than Novo Nordisk AS, analysts believe Viking Therapeutics is more attractive than Novo Nordisk AS.

Novo Nordisk AS has a beta of 0.642, which suggesting that the stock is 35.798% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.623, suggesting its less volatile than the S&P 500 by 37.744%.

Novo Nordisk AS has a quarterly dividend of $1.14 per share corresponding to a yield of 2.48%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk AS pays 43.71% of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novo Nordisk AS quarterly revenues are $11B, which are larger than Viking Therapeutics quarterly revenues of --. Novo Nordisk AS's net income of $4.1B is higher than Viking Therapeutics's net income of -$45.6M. Notably, Novo Nordisk AS's price-to-earnings ratio is 19.85x while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 6.85x versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.